|
|
Blood, 1 January 2006, Vol. 107, No. 1, pp. 232-240.
Prepublished online as a Blood First Edition Paper on September 15, 2005; DOI 10.1182/blood-2005-06-2302.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism
Girija Dasmahapatra,
Mohamed Rahmani,
Paul Dent, and
Steven Grant
From the Department of Medicine and Department of Radiation Oncology, Virginia Commonwealth University, Richmond.
Interactions between the tyrphostin adaphostin and proteasome inhibitors (eg, MG-132 and bortezomib) were examined in multiple human leukemia cell lines and primary acute myeloid leukemia (AML) specimens. Cotreatment of Jurkat cells with marginally toxic concentrations of adaphostin and proteasome inhibitors synergistically potentiated mitochondrial damage (eg, cytochrome c release), caspase activation, and apoptosis. Similar interactions occurred in other human leukemia cell types (eg, U937, HL-60, Raji). These interactions were associated with a marked increase in oxidative damage (eg, ROS generation), down-regulation of the Raf/MEK/ERK pathway, and JNK activation. Adaphostin/MG-132 lethality as well as mitochondrial damage, down-regulation of Raf/MEK/ERK, and activation of JNK were attenuated by the free-radical scavenger NAC, suggesting that oxidative damage plays a functional role in antileukemic effects. Ectopic expression of Raf-1 or constitutively active MEK/ERK or genetic interruption of the JNK pathway significantly diminished adaphostin/MG-132-mediated lethality. Interestingly, enforced Raf or MEK/ERK activation partially diminished adaphostin/MG-132-mediated ROS generation, suggesting the existence of an amplification loop. Finally, the adaphostin/MG-132 regimen displayed similar toxicity toward 5 primary AML samples but not normal hematopoietic progenitors (eg, bone marrow CD34+ cells). Collectively, these findings suggest that potentiating oxidative damage by combining adaphostin with proteasome inhibitors warrants attention as an antileukemic strategy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
ROS `n' roll: a bunch of JNK?
- Steven D. Gore
Blood 2006 107: 9-10.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
Y. H. HAN, H. J. MOON, B. R. YOU, S. Z. KIM, S. H. KIM, and W. H. PARK
The Effect of MAPK Inhibitors on Arsenic Trioxide-treated Calu-6 Lung Cells in Relation to Cell Death, ROS and GSH Levels
Anticancer Res,
October 1, 2009;
29(10):
3837 - 3844.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Fasanaro, M. C. Capogrossi, and F. Martelli
Regulation of the endothelial cell cycle by the ubiquitin-proteasome system
Cardiovasc Res,
August 7, 2009;
(2009)
cvp244v2.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. H. Han, S. Z. Kim, S. H. Kim, and W. H. Park
Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis
Am J Physiol Renal Physiol,
August 1, 2007;
293(2):
F511 - F520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Stockwin, M. A. Bumke, S. X. Yu, S. P. Webb, J. R. Collins, M. G. Hollingshead, and D. L. Newton
Proteomic Analysis Identifies Oxidative Stress Induction by Adaphostin
Clin. Cancer Res.,
June 15, 2007;
13(12):
3667 - 3681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Bartholomeusz, M. Talpaz, V. Kapuria, L. Y. Kong, S. Wang, Z. Estrov, W. Priebe, J. Wu, and N. J. Donato
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
Blood,
April 15, 2007;
109(8):
3470 - 3478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, M. M. Zeigler, G. K. Lam, M. G. Hunter, T. D. Eubank, V. V. Khramtsov, S. Tridandapani, C. K. Sen, and C. B. Marsh
The Role of the NADPH Oxidase Complex, p38 MAPK, and Akt in Regulating Human Monocyte/Macrophage Survival
Am. J. Respir. Cell Mol. Biol.,
January 1, 2007;
36(1):
68 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy
Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS
J. Biol. Chem.,
December 8, 2006;
281(49):
37330 - 37344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. E. Kay
ROS: double-edged sword for leukemic cells
Blood,
March 15, 2006;
107(6):
2212 - 2213.
[Full Text]
[PDF]
|
 |
|
|
|